Mohammad Hussain, MD

Mohammad Hussain, MD

Assistant Professor, Hematology/Oncology, Department of Internal Medicine
Hematology / Oncology

    About me

    Gender

    Male

    Education & training

    Positions
    Hematologist/Oncologist
    Board Certifications
    Internal Medicine
    Medical Oncology
    Hematology
    Medical School
    Allama Iqbal Medical College University of Punjab, Pakistan
    Residency
    Pinnacle Health Hospitals, Harrisburg, PA (UPMC)
    Fellowship
    Hematology and Oncology, Levine Cancer Institute, Charlotte, NC and Blood and Marrow Transplant, Stanford University School of Medicine

    Clinical trials

    Trial
    Simmons Cancer Institute

    KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

    Active recruiting

    Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

    Active recruiting

    The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .

    Contact: Kathy Robinson 217-545-1946